Literature DB >> 20473164

Locally advanced cervical cancer: what is the standard of care?

Zeina Al-Mansour1, Claire Verschraegen.   

Abstract

PURPOSE OF REVIEW: Carcinoma of the cervix remains a significant health problem for women worldwide. Locally advanced cervical cancer (LACC) is a common presentation that has been extensively studied in the last three decades. This article reviews the standard of care and discusses current topics of clinical research. RECENT
FINDINGS: A multidisciplinary approach to the treatment of cervical cancer has led to marked improvement in outcome. Main advances are with neoadjuvant chemotherapy, chemoradiation, and preventive vaccination. Concurrent chemoradiation with a platinum-based agent is the recommended treatment for LACC. Palliation with platinum agent remains the standard of care for inoperable patients who have metastatic or recurrent disease.
SUMMARY: This is a review of published and ongoing studies testing multidisciplinary and medical management of LACC, with a focus on newer chemotherapeutic approaches. Optimal multidisciplinary treatment planning improves the outcome of each patient diagnosed with cervical cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20473164     DOI: 10.1097/CCO.0b013e32833af426

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  17 in total

1.  Treatment of cervical cancer: the importance of a multidisciplinary team approach.

Authors:  J Alejandro Pérez Fidalgo; Ana Hernández Machancoses; Víctor Martín González; Andrés Cervantes
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

Review 2.  Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.

Authors:  David Howard; Jetzabel Garcia-Parra; Gareth D Healey; Cynthia Amakiri; Lavinia Margarit; Lewis W Francis; Deyarina Gonzalez; R Steven Conlan
Journal:  Interface Focus       Date:  2016-12-06       Impact factor: 3.906

Review 3.  'BRCAness' and its implications for platinum action in gynecologic cancer.

Authors:  Franco Muggia; Tamar Safra
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

4.  Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.

Authors:  Si Gao; Siyao Du; Zaiming Lu; Jun Xin; Song Gao; Hongzan Sun
Journal:  Eur Radiol       Date:  2019-09-06       Impact factor: 5.315

5.  The Microenvironment of Cervical Carcinoma Xenografts: Associations with Lymph Node Metastasis and Its Assessment by DCE-MRI.

Authors:  Christine Ellingsen; Stefan Walenta; Tord Hompland; Wolfgang Mueller-Klieser; Einar K Rofstad
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

6.  Molecular markers of DNA damage and repair in cervical cancer patients treated with cisplatin neoadjuvant chemotherapy: an exploratory study.

Authors:  Nilda E Real; Gisela N Castro; F Darío Cuello-Carrión; Claudia Perinetti; Hanna Röhrich; Niubys Cayado-Gutiérrez; Martin E Guerrero-Gimenez; Daniel R Ciocca
Journal:  Cell Stress Chaperones       Date:  2017-06-12       Impact factor: 3.667

7.  Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease.

Authors:  Denise L Jacobson; Athos Bousvaros; Lori Ashworth; Rebecca Carey; Lydia A Shrier; Sandra K Burchett; Harmony Renna; Ying Lu
Journal:  Inflamm Bowel Dis       Date:  2013-06       Impact factor: 5.325

Review 8.  Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB.

Authors:  Lucas Minig; María Guadalupe Patrono; Nuria Romero; Juan Francisco Rodríguez Moreno; Jesús Garcia-Donas
Journal:  World J Clin Oncol       Date:  2014-05-10

9.  Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer.

Authors:  Yu Jung Kim; Mark F Munsell; Ji Chan Park; Larissa A Meyer; Charlotte C Sun; Alaina J Brown; Diane C Bodurka; Janet L Williams; Dana M Chase; Eduardo Bruera; Lois M Ramondetta
Journal:  Gynecol Oncol       Date:  2015-09-30       Impact factor: 5.482

10.  Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer.

Authors:  Tae Wook Kong; Suk-Joon Chang; Jiheum Paek; Seung-Chul Yoo; Jong-Hyuck Yoon; Ki-Hong Chang; Mison Chun; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.